<DOC>
	<DOCNO>NCT00616785</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan , cisplatin , etoposide work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-rays damage tumor cell . Giving combination chemotherapy together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give combination chemotherapy together radiation therapy work treat patient stage III non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate efficacy induction chemotherapy comprise irinotecan hydrochloride cisplatin patient locally advance , unresectable stage III non-small cell lung cancer . - To evaluate feasibility radiotherapy administer concurrently etoposide cisplatin chemotherapy induction chemotherapy patient . Secondary - To evaluate toxicity induction chemotherapy comprise irinotecan hydrochloride cisplatin patient . - To assess whether induction chemotherapy regimen improve patient survival compare outcomes predecessor study , SWOG-9019 . OUTLINE : Patients receive dose-dense induction chemotherapy comprise irinotecan hydrochloride IV cisplatin IV day 1 8 . Treatment repeat every 21 day 2 course . After completion induction chemotherapy , patient undergo radiotherapy five day week approximately 7 week . Patients receive concurrent chemotherapy comprise cisplatin IV day 1 , 8 , 29 , 36 etoposide IV day 1-5 29-33 . After completion study therapy , patient follow 6 week .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IIIA ( N2 ) IIIB disease Pathologic documentation N23 mediastinal lymph node encourage require nodal size ≥ 1.5 cm large diameter No stage IIIB disease malignant pleural effusion superior sulcus tumor At least one measurable lesion define Response Evaluation Criteria Solid Tumors Unresectable disease No known brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month ANC ≥ 1,500/mm³ Hemoglobin ≥ 9.0 g/dL ( correct transfusion ) Platelet count ≥ 100,000/mm³ Creatinine &lt; 1.5 mg/dL Total bilirubin &lt; 2 time upper limit normal ( ULN ) Transaminases &lt; 3 time ULN Patient compliance geographic proximity allow adequate follow No serious , uncontrolled systemic intercurrent illness ( e.g. , infection poorly control diabetes ) No history significant neurological mental disorder , include seizure dementia No malignancy within past 5 year except carcinoma situ cervix nonmelanoma skin cancer No active cardiac disease control therapy No myocardial infarction within past 12 month PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy NSCLC No concurrent systemic chemotherapy , investigational drug , radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>